Session Information
Date: Sunday, November 8, 2026
Title: (0093-0103) Rheumatoid Arthritis - Etiology & Pathogenesis Poster A
Session Type: Poster Session A
Session Time: 10:30AM-12:30PM
Background/Purpose: Persons with rheumatoid arthritis (RA) are known to have lower antibody responses to primary series COVID-19 vaccine, and immunosuppressive medications used to treat RA are thought to be at least in part responsible. At the same time, additional doses of COVID vaccine have been thought to ameliorate this gap. We have previously observed lower antibody and T cell response to the primary 2 dose COVID mRNA vaccine series in persons with RA, and this was associated with age, RA disease status and medications used to treat RA. Here we sought to understand whether additional vaccine doses could close the gap in COVID vaccine induced immunity comparing RA patients and controls.
Methods: We evaluated serum samples taken in a cross sectional cohort of RA patients (n=99) and non-autoimmune disease controls (n=131), for anti-spike IgG levels to Wuhan, BA.1, BA.5, XBB1.5, JN.1, and KP.2 spike protein, and analyzed results with regard to time since last vaccine dose, number of vaccine doses, evidence of prior COVID exposure (presence of nucleocapsid protein (NCP) antibody), age, race, sex and RA treatment. Additionally, we assessed peripheral blood mononuclear cells (PBMC) for spike-specific IFN-γ and IL-2 production by ELISPOT assay and compared between RA and control groups.
Results: In models adjusting for number of doses of vaccine, time since last vaccine, NCP antibody status, sex and age, RA participants had lower Wuhan, BA.1, BA.5, XBB.1.5, JN.1, and KP.2 spike protein spike-specific IgG levels than controls. Wuhan antibody levels were lowest in RA participants taking conventional disease modifying antirheumatic drugs (DMARDS), abatacept or rituximab, and, antibody levels were higher in participants that had 3+ doses of vaccine compared to those with 2 doses. Spike specific PBMC IFN-γ and IL-2 producing immunity was similar comparing RA and control groups.
Conclusion: These data indicate lower COVID-19 mRNA vaccine-induced antibody levels in persons with RA compared to individuals without RA persist after over 2 doses of vaccine, after adjusting for number of vaccine doses, recent infection, and time since vaccine. This diminished response is likely in part attributable to immune modulatory therapies used to treat RA. At the same time, cellular immune response to COVID-19 vaccines is comparable between RA and control groups.
To cite this abstract in AMA style:
Chitti M, Behrens S, Kostadinova L, Dudley H, O'mara M, Hall E, Allamon L, Silversteyn L, Malakooti S, King C, Bosh J, Canaday D, Zidar D, Mattar M, Wilson B, Shive C, Anthony D. Rheumatoid Arthritis Remains Associated with Lower Humoral but not Cellular Immune Response Beyond Primary COVID mRNA Vaccine Series in US Veterans [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/rheumatoid-arthritis-remains-associated-with-lower-humoral-but-not-cellular-immune-response-beyond-primary-covid-mrna-vaccine-series-in-us-veterans/. Accessed .ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-arthritis-remains-associated-with-lower-humoral-but-not-cellular-immune-response-beyond-primary-covid-mrna-vaccine-series-in-us-veterans/
